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There is growing interest in quantitative analysis
of in vivo genetic toxicity dose-response data,
and use of point-of-departure (PoD) metrics such
as the benchmark dose (BMD) for human health
risk assessment (HHRA). Currently, multiple
transgenic rodent (TGR) assay variants, employ-
ing different rodent strains and reporter trans-
genes, are used for the assessment of
chemically-induced genotoxic effects in vivo.
However, regulatory issues arise when different
PoD values (e.g., lower BMD confidence inter-
vals or BMDLs) are obtained for the same com-
pound across different TGR assay variants. This
study therefore employed the BMD approach to
examine the ability of different TGR variants to
yield comparable genotoxic potency estimates.
Review of over 2000 dose-response datasets
identified suitably-matched dose-response data
for three compounds (ethyl methanesulfonate or
EMS, N-ethyl-N-nitrosourea or ENU, and
dimethylnitrosamine or DMN) across four
commonly-used murine TGR variants (Muta-
TMMouse lacZ, MutaTMMouse cII, gpt delta and
BigBlueVR lacI). Dose-response analyses provided
no conclusive evidence that TGR variant choice
significantly influences the derived genotoxic
potency estimate. This conclusion was reliant
upon taking into account the importance of
comparing BMD confidence intervals as
opposed to directly comparing PoD values
(e.g., comparing BMDLs). Comparisons with
earlier works suggested that with respect to
potency determination, tissue choice is poten-
tially more important than choice of TGR assay
variant. Scoring multiple tissues selected on the
basis of supporting toxicokinetic information is
therefore recommended. Finally, we used typical
within-group variances to estimate preliminary
endpoint-specific benchmark response (BMR) val-
ues across several TGR variants/tissues. We
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discuss why such values are required for routine
use of genetic toxicity PoDs for HHRA. Environ.
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INTRODUCTION
Genetic toxicity testing is an essential component of
safety assessments for new and existing substances (e.g.,
food additives, therapeutic products, pesticides, industrial
chemicals). Its goal is to identify genotoxic substances
and/or assess genotoxic potency, thus permitting regula-
tory decisions that minimize the risk of adverse human
health effects (e.g., cancer and heritable genetic disorders)
mediated by genetic damage. Traditionally, genetic toxic-
ity tests have been interpreted qualitatively, with yes-or-
no calls used to merely identify agents that have the
ability to cause genetic damage (e.g., mutations and/or
chromosomal aberrations). Increasingly however, there is
growing interest in moving beyond binary categorizations
that fail to acknowledge and appreciate variations in the
genotoxic potency of tested agents (i.e., variations in the
magnitude of the effect associated with a given dose).
The alternative quantitative methods employ statistical
analyses of genotoxicity dose-response data to determine
a point-of-departure (PoD) that provides quantitative
information regarding genotoxic potency. Resultant PoDs,
such as the lower confidence interval of the benchmark
dose (i.e., the BMDL), can be used as a basis for quanti-
tative risk assessments, including the derivation of human
exposure limits and/or margins of exposure (MOEs).
Thus, employment of quantitative methods, which
acknowledge the relevance of genetic toxicity as a bona
fide regulatory endpoint, permit the determination of val-
ues that can be used for human health risk assessment
(HHRA) and regulatory decision-making. Indeed, recent
evaluations by several expert working groups have
acknowledged the regulatory utility of quantitative dose-
response analyses of genetic toxicity data [Johnson et al.,
2015; MacGregor et al., 2015a,b; White and Johnson,
2016].
The transgenic rodent (TGR) gene mutation assays are
well-established in vivo assays for the assessment of
chemically-induced genetic toxicity. Critically, they pro-
vide reliable measurements of dose-related inductions of
gene mutations in practically any tissue. Briefly, TGR
assays employ transgenic rodents (e.g., rats or mice) har-
boring multiple copies of stable, chromosomally inte-
grated plasmids or bacteriophage shuttle vectors to
determine a test article’s ability to induce mutations at a
transgenic target locus (e.g., lacI, lacZ, cII, and gpt). Fol-
lowing exposure to the test article, transgene mutations in
selected tissues are detected by retrieving the vector and
determining the phenotype of the reporter gene in a bac-
terial host [Douglas, 2010; Lambert et al., 2005].
In 2011, the Organisation for Economic Co-operation
and Development (OECD) published a test guideline (i.e.,
TG 488) for estimating the induction of in vivo somatic
and germ cell gene mutations using TGR assays, thus
contributing to the harmonization of TGR protocols
employed to assess chemically-induced, in vivo genetic
damage [OECD, 2011]. The detailed review paper that
preceded TG 488 noted that multiple variants of the TGR
assay, which employ different rodent species and/or
reporter transgenes, are available for regulatory evalua-
tions of test articles [Lambert et al., 2005]. More specifi-
cally, when TG 488 was released there was considered
sufficient information to demonstrate the utility of the fol-
lowing TGR assay variants: MutaTMMouse (lacZ and cII
transgenes), Big Blue
VR
mouse and rat (lacI and cII trans-
gene), plasmid mouse (lacZ), and gpt delta mouse and rat
(gpt) [Douglas, 2010]. The results generated using these
TGR assays constitute a useful follow-up of in vitro posi-
tives; moreover, TGR results can augment regulatory
decision-making when cancer bioassay results are absent,
marginal or inconclusive [Douglas, 2010; Lambert et al.,
2005; OECD, 2011; Soeteman-Hernandez et al., 2016].
The value of the TGR assay for the evaluation of
human health risks resultant from exposure to genotoxic
substances was recently demonstrated in a landmark case
involving human exposure to ethyl methanesulfonate
(EMS), a potent mutagenic carcinogen. More specifically,
between March and June 2007 a batch of Viracept
VR
(i.e.,
nelfinavir mesylate), an antiretroviral protease inhibitor,
was accidently contaminated with EMS, resulting in a
global recall of the drug [Pozniak et al., 2009]. Since
existing data was considered inadequate for effective
patient risk management, a comprehensive MutaTMMouse
study of EMS was carried out. The analyses scored
micronucleus frequency in bone marrow and lacZ muta-
tions in selected tissues (e.g., small intestine, liver, bone
marrow) following 28-day repeat dose oral exposure. The
results were used to demonstrate that the minimal dose
required to elicit a significant increase in the
MutaTMMouse response (i.e., 25 mg/kg/day) is approxi-
mately 450-fold greater than the maximum amount
ingested by patients receiving the product (i.e., 0.055 mg/
kg/day). These analyses were used to conclude that the
risk of adverse health effects in individual patients receiv-
ing the contaminated product were negligible [Muller and
Gocke, 2009; Muller, et al. 2009; Pozniak et al., 2009)].
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The Viracept
VR
contamination incident stimulated the
formation of several international working-groups that
evaluated different statistical approaches for quantitative
analysis of genetic toxicity dose-response data [Gollapudi
et al., 2013; Johnson et al., 2014, 2015; MacGregor et al.,
2015a,b]. These works led to general agreement that the
benchmark dose (BMD) approach, which is increasingly
used for the evaluation of other toxicity dose-response
data, also provides the most appropriate method for the
quantitative interpretation of genetic toxicity dose-
response data [Gollapudi et al., 2013; Johnson et al.,
2014; MacGregor et al., 2015a,b]. The BMD approach
involves statistical analysis of the dose-response relation-
ships to define the dose (i.e., the BMD) required to elicit
a pre-specified small increase in response (i.e., the BMR
or Benchmark Response) [Crump, 1984; EFSA, 2009,
2017; Slob, 2002]. Figure 1 schematically illustrates the
BMD approach, and how the BMD can be used to quanti-
tatively define genotoxic potency. As data are always lim-
ited (i.e., limited number of doses and replicates) the true
BMD can never be defined exactly, and hence reporting a
BMD confidence interval that can be expected to include
the true BMD with a defined level of confidence is pref-
erable over reporting of a single point estimate of the
BMD. The lower and upper bounds of the BMD confi-
dence interval are called BMDL and BMDU, respec-
tively. The ratio of BMDU-to-BMDL thus reflects the
uncertainty (i.e., imprecision) in the BMD estimate in
accordance with the quality of the underlying data [Wills
et al., 2016a].
More recent advances of the BMD methodology permit
simultaneous analyses of multiple dose-response datasets
for a common endpoint and study design (Fig. 1) in one
combined analysis. This approach, which is known as the
combined BMD covariate method, uses inclusion of a
covariate (e.g., compound, sex, species, etc.) to identify
constituent dose-response sub-groupings [Slob, 2002;
Slob and Setzer, 2014]. Critically, it has been shown that
this combined approach can improve the precision of
each individual BMD estimate (i.e., bring about a reduc-
tion in BMDU-to-BMDL ratios) as all dose-response
datasets included in a combined analysis contribute infor-
mation to any individual BMD estimate under consider-
ation [Slob and Setzer, 2014; Wills et al., 2016a,b].
Fig. 1. Schematic overview of the BMD combined covariate approach.
The benchmark dose approach (BMD) provides an estimate of the dose
that will elicit a small, pre-specified effect-size called the benchmark
response (BMR). The best-fitting BMD model (solid curve) will result in
the best estimate of the BMD. Importantly however, the uncertainty in
the dose-response data needs to be accounted for through calculation of a
BMD confidence interval. The process can be conceptually visualized by
imagining that, through variation of the model parameters, other curves,
and BMDs that plausibly describe the data (e.g., schematically repre-
sented by the dashed curves) may be established. Together these values
comprise the BMD confidence interval (solid line). In turn, this process
provides estimations of the BMDL (L) and BMDU (U), the lower and
upper 90% confidence bounds of the BMD estimate, respectively.
Therefore, the ratio of the BMDU to BMDL represents the precision to
which the true BMD can be estimated based on the available dose-
response data. A newer method termed the combined, BMD-covariate
approach allows BMDs for multiple dose-response curves to be defined in
one combined analysis employing a covariate such as compound, expo-
sure regime, time, sex, or species to identify the constituent dose-response
relationships. The major advantage of this approach is that any model
parameters that are determined to be similar across covariate subgroup-
ings may be held constant during an analysis; thus their estimation is
based on all the dose-response curves included in the combined analysis.
Concomitantly, the precision of the BMD estimate is improved (i.e.,
reduced BMDU-to-BMDL ratio) for any individual dataset under
consideration.
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Following on from the aforementioned MutaTMMouse
(lacZ) study of EMS (i.e., analyses related to the
ViraceptVR contamination incident), a 2014 study repeated
the work using a matching study design, but, instead
employed the gpt delta mouse (gpt transgene) TGR assay
[Cao et al., 2014]. The specific aim of this work was to
utilize quantitative methods to compare genotoxic potency
estimates for two TGR assay variants with well character-
ized differences in spontaneous mutant frequency (i.e.,
background). The authors noted that the tissue-specific
BMDL10 values associated with the gpt delta mouse data
were lower than those calculated from MutaTMMouse
data. Subsequently, these divergent results triggered an
international response from multiple working groups
regarding the regulatory issues associated with differences
in BMDL values obtained across different TGR assay
variants.
In response to these concerns about cross-study differ-
ences in the transgenic rodent BMDL values for EMS,
the Quantitative Analysis Workgroup of the International
Life Sciences Institute (ILSI) Health and Environmental
Sciences Institute (HESI) Genetic Toxicology Technical
Committee (GTTC) prioritized quantitative examination
of published TGR dose-response data. More specifically,
quantitative analyses assessing the ability of different
TGR assay variants to yield comparable estimates of gen-
otoxic potency were established as a priority. This work
required an initial meta-analysis of all available TGR data
to identify compounds, including EMS, that have been
tested using two or more TGR assay variants. To ensure
robust comparisons, datasets were screened to identify
those that are also suitably matched with respect to tissue,
route of administration, application schedule, and sam-
pling time. Herein, we thus use the BMD approach to
evaluate the quantitative agreement in genotoxic potency
estimates resulting from employment of different TGR
assay variants. We also assess and discuss the importance
of appropriately defining benchmark response values
(BMRs), also known as critical effect sizes (CES).
MATERIALS ANDMETHODS
Data Collection
TGR assay dose-response data were obtained from the latest version
of the Transgenic Rodent Assay Information Database (TRAID). TRAID
is a database containing dose-response data for all publicly available
TGR studies published as of August 31, 2016. The current version,
which was updated by screening PubMed and Scopus using the search
string ((“MutaMouse” OR “Big Blue” OR “lacZ” OR “lacI” OR “gpt”
OR “cII”) AND (mutation OR mutant OR mutagen OR mutagenesis))
AND (mouse OR rat OR rodent OR mice OR rats OR rodents), is an
updated version of the original database compiled by Lambert et al.
(2005). Briefly, the database contains 9716 records representing 2127
dose-response datasets from 406 studies on 307 test articles, including
dose-response data for five transgenes (e.g., lacZ, lacI, cII, gpt, and red/
gam), 31 tissues, and 25 administration routes. The complete dataset
was screened using SAS v9.4 to identify suitably matched dose-response
data for compounds that have been examined using more than one TGR
assay. For the purposes of this study, compound-specific dose-response
data were only retained if data were available in two or more TGR assay
variants, if the studies used three or more dose-groups (i.e., suitable for
BMD modeling), and if the datasets could be matched for tissue, route
of administration, exposure duration, and sampling time. This stringent
screening criteria revealed only five compounds that have been tested in
two or more TGR assays using analogous study design (i.e., EMS,
N-ethyl-N-nitrosourea or ENU, chlorambucil, dimethylnitrosamine or
DMN, and diethylnitrosamine or DEN). Of these, 14 dose-response data-
sets across three of the compounds (i.e., EMS, ENU, and DMN) utilized
a sufficient number of dose groups (31) to be suitable for BMD analy-
sis. The full extent of dataset matching in terms of study covariates for
each presented analysis is presented in Supporting Information Table SI,
alongside the data-source citations.
BMDAnalysis
BMD analyses (i.e., statistical analysis of the dose-response data)
were conducted using PROAST software version 63.6 in the R comput-
ing environment (Dutch National Institute for Public Health and the
Environment (RIVM)). PROAST v38.9 is available for free download at
http://www.proast.nl. More recent versions (e.g., 63.6) can be obtained
from one of the authors (i.e., Wout Slob). Datasets were analyzed using
both the exponential and the Hill model families as recommended by
the European Food Safety Authority (EFSA) for the assessment of con-
tinuous data [EFSA, 2009, 2017]. Where the combined BMD-covariate
approach was used, the factor discriminating the dose-response sub-
groupings was included as covariate (e.g., study or transgene). For the
combined BMD-covariate approach, the model parameters that require
estimation for each subgroup, alongside those that can be considered
constants across subgroups, are determined. Combined analyses typically
assumed that model ‘shape’ parameters ‘c’ and ‘d’ (i.e., maximum
response and log-steepness after axis scaling) were constant across sub-
groups, whilst the parameters ‘a’, ‘b’, and ‘var’ (background response,
potency, and within-group variation, respectively) were tested for sub-
grouping dependency. BMD analyses and model fits for each subgroup-
ing are presented in Supporting Information Figures S1-S4, with the
model fits used to visually assess the validity of the conserved shape
assumption. This approach was preferred to statistical testing as statisti-
cal tests on the BMD model shape parameters (i.e., c, d) have been
shown to be extremely sensitive to the non-random errors that are ubiq-
uitously present in experimental dose-response data since it is not practi-
cally feasible to randomize all experimental conditions and concomitant
treatments. Critically, due to the statistical power arising in a combined
dataset, even small non-random errors in the data can result in rejection
of shape parameter consistency. In reality however, such small differ-
ences in shape parameters can only, at most, have a very minor effect
on the coverage of the calculated confidence intervals [Slob and Setzer,
2014].
The BMDL and BMDU values represent the two-sided, lower and
upper 90% BMD confidence intervals, respectively, thus the BMDU-to-
BMDL ratio defines the BMD estimate precision. Confidence interval
plots were employed to visually compare differences in potency, in order
to take estimation uncertainty into account [Bemis et al,. 2016; Wills
et al., 2016a,b]. Dose-response relationships across subgroupings (e.g.,
different TGR assay variants) can only be termed significantly different
where confidence intervals do not overlap. Where employed, endpoint-
specific BMR values were calculated in the PROAST software as the
control-group mean plus one typical standard deviation. Briefly, this
typical value of the standard deviation, which was calculated on the log-
scale, was defined as the average within-group standard deviation calcu-
lated across all dose-groups and studies included in a combined BMD
analysis. The full rationale for this choice, and the importance of its
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calculation on the log-scale, is discussed at length in Slob (2017) and its
accompanying annexes. To facilitate comparisons to fixed percentage
effect sizes (e.g., BMR5 10%), resultant endpoint-specific BMRs were
expressed as percentage increases relative to the control-group mean.
The calculated BMD values underlying the confidence interval plots
show in each analysis are provided in Supporting Information Table SII.
RESULTS ANDDISCUSSION
A Survey of TGR Studies to Identify Matched Dose-
Response Datasets
In order to compare genotoxic potency estimates
derived from dose-response data generated using different
variants of the TGR assay (i.e., different strains and/or
transgenes), a meta-analysis filtration of the TRAID data-
base was performed (see Methods) to identify suitably-
matched datasets (i.e., in terms of compound, species, tis-
sue, administration route, exposure duration, sampling
time) that are thus well-suited for potency estimate com-
parisons. Scrutiny of over 9700 records containing over
2000 dose-response datasets identified only 14 datasets
that fulfilled the screening criteria (detailed in Supporting
Information Table SI). The comparison of these matched
studies form the basis of the results presented herein.
In consideration of the findings of the meta-analysis,
the relatively low number of matching datasets is indica-
tive of the variability of study designs historically
employed within and between different TGR assay var-
iants. Thus, these findings alone suggest the importance
of global harmonization initiatives (e.g. OECD TG 488)
in facilitating the maximum utility of TGR dose-response
data. Cross-study comparisons are simplified when results
are generated using analogous methods and study design
as this dramatically reduces the number of potentially
influential covariates. In turn, consistent dose-response
data are also better-suited to support human health risk
assessments, whereby findings are often compared across
studies during the process of weight-of-evidence based
regulatory decision-making [Dearfield et al., 2017;
MacGregor et al., 2015a].
Use of the BMDApproach to Compare Potencies and
Assess Inter-Study Reproducibility
In previous publications, we showed that comparisons
of BMD confidence intervals (see Fig. 1), as opposed to
direct comparison of single metric (i.e., BMD, BMDL or
BMDU), constitutes a robust way to quantitatively exam-
ine differences in potency across dose-response relation-
ships [Bemis et al., 2016; Soeteman-Hernandez et al.,
2016; Wills et al., 2016a,b]. Considering BMD confidence
intervals for the purposes of comparisons between studies
is critical, since they reflect the uncertainty in the potency
estimate as a result of the uncertainties in the underlying
dose-response data (e.g., due to random sampling errors
between replicates). Consequently, one can only conclude
that dose-response relationships and potency estimates
(e.g., BMDs) arising from, for example, assessments of
the same compound across different variants of the TGR
assay, are significantly different when their BMD confi-
dence intervals do not overlap [Wills et al., 2016a,b]. In
contrast, overlapping confidence intervals signify that any
potency differences cannot be resolved on the basis of the
available data (i.e., the true BMDs could be the same, or
could differ). Critically, when the range delineated by all
the confidence intervals examined is small enough to be
considered as biologically or practically insignificant, it
may be concluded that the potencies are sufficiently
similar to consider the associated studies reproducible
[Johnson et al., 2016; Wills et al., 2016a,b].
EMS: Comparisons of gpt-Delta Mouse (gpt) and
MutaTMMouse (lacZ) Dose-Response Data for Bone
Marrow, Small Intestine and Liver
In their analysis of EMS dose-response data across two
TGR variants (MutaTMMouse (lacZ) and gpt delta
mouse), Cao et al., (2014) noted lower BMDL10 values
associated with the gpt delta mouse data (see introduc-
tion). Critically however, this finding cannot be inter-
preted as evidence of poor potency estimate
comparability between the two TGR assay variants, since,
as noted, potency comparisons should not be based on
any single BMD or BMDL value, but rather on compari-
sons of complete BMD confidence intervals. In their com-
bined BMD analysis, Cao et al., (2014) also used ‘tissue’
as a dose-response covariate: this choice of covariate is
potentially problematic since any correlation between tis-
sues harvested from the same animals could give rise to
overly optimistic (i.e., narrow) BMD confidence intervals.
Thus, in the analyses presented below, we chose to carry
out pairwise combined BMD analyses tissue-by-tissue
using ‘TGR’ as covariate.
Applying this approach (i.e., confidence interval com-
parison and TGR as covariate), Figure 2 presents a
reanalysis of the EMS dose-response data for the gpt
delta mouse [Cao et al., 2014] and MutaTMMouse [Gocke
et al., 2009] TGR systems. Consideration of the bone
marrow and small intestine results shows that whereas the
gpt delta mouse BMDL10 values are consistently lower
than the matched MutaTMMouse values, the confidence
intervals show considerable overlap. This means that the
BMDs could, in fact, be identical and thus the available
data do not allow us to conclude that the assay results are
non-reproducible. In turn, the BMD confidence intervals
also give an indication of how large the differences
between the assays might be. In this example, the range
spanned by the confidence intervals for bone marrow and
small intestine indicate that, at most, the genotoxic
potency estimates may differ by 0.6 log units. Thus, on
the basis of the available data, it can only be concluded
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that the difference in potency estimates arising across
these two assays may be anywhere between zero and 0.6
log units (i.e., 0 to 4-fold).
Interestingly, comparison of the liver data shows an
infinite lower bound of the BMD (represented by the
dashed interval) for the gpt delta mouse data when the
BMD10 was calculated using the Hill model, whereas
the BMDL was calculable using the exponential model.
An infinite lower bound indicates a dose-response rela-
tionship whereby the data only allow us to conclude that
any dose greater than zero might elicit the specified BMR
(i.e., 10% for this analysis). Thus, such a finding typically
reflects uncertainty in the dose-response data within the
response region interpolated at the effect size (i.e. BMR).
Closer scrutiny of the liver datasets (Supporting Informa-
tion Figure S1) illustrates that the two TGR variants show
opposite dose-response patterns. More specifically, for the
gpt delta mouse, the mean response in the lowest dose-
group is higher than control, yet the response does not
subsequently increase further with increasing dose. In
contrast, for the MutaTMMouse dataset, only the mean
response in the highest dose-group indicates a response
that is marginally increased relative to background. Thus,
it seems likely that for the gpt delta mouse liver dataset,
the control-group response is an outlier and that no true
dose-response is established across the tested dose-range.
Similarly, for the MutaTMMouse liver data set, the highest
dose-group might represent an outlier. Thus, without fur-
ther (i.e., higher) dose-groups to clearly establish the
dose-response relationships in this tissue, these datasets
are not suitable for dose-response analysis. This uncer-
tainty is reflected in the aforementioned unbounded BMD
confidence interval for the gpt delta mouse data, whereas
the confidence interval established from the
MutaTMMouse liver data shows that, even if the apparent
response in the highest dose group is a true dose-related
effect, liver is less sensitive than the other two tissues. In
a wider context, the difference between the exponential
and Hill model confidence intervals arising from the gpt
delta mouse liver data exemplifies the importance of car-
rying out BMD analyses using both model families (i.e.,
exponential and Hill) to ensure the uncertainty in BMD
estimates is thoroughly characterized. This is particularly
important when a robust estimate of genotoxic potency is
essential for (e.g. for HHRA purposes), as has been
advocated previously [EFSA, 2016; Johnson et al., 2014;
MacGregor et al., 2015b; Slob and Setzer, 2014].
When carrying out BMD analyses on large combined
datasets, the choice of the BMR percentage has been
shown to be fairly unimportant for the purposes of objec-
tively comparing genotoxic potencies [Bemis et al.,
2016]. However, each combined analysis conducted
herein only involved a small number of datasets, thus the
precision of the BMD estimate decreases with choice of
smaller and thus more difficult-to-estimate effect sizes
(i.e., smaller BMRs). Indeed, in the above EMS analysis,
the BMR of 10% was more or less arbitrarily chosen on
the basis of no more than the fact that it is often used in
the analysis of toxicological dose-response data. On the
other hand, when the purpose of the analysis is to derive
BMD values for HHRA purposes, it becomes necessary
to define a defensible, meaningful small BMR size for
that can be utilized as a basis for the robust determination
of HHRA metrics (e.g., permitted daily exposure or PDE,
Fig. 2. Genotoxic potency of ethyl methanesulphonate (EMS) deter-
mined using the gpt delta Mouse (red) and MutaTMMouse (blue) trans-
genic rodent assays. BMD analyses, with TGR as covariate, were
conducted to compare potency values (i.e., BMDs) determined using two
different TGR assay variants. Two-sided 90% confidence intervals of the
BMD10 (i.e., BMR5 10%) were calculated from mutant frequency (MF)
dose-response data (i.e., gpt or lacZ MF) for bone marrow, small
intestine, and liver tissues using two different BMD models: the exponen-
tial (upper interval per pair) or the Hill (lower interval per pair). Com-
bined analyses were performed, two datasets at a time by tissue, using
TGR as covariate. The dashed liver interval for the Hill model indicates
an unbounded lower confidence limit (i.e., BMDL5 0). The underlying
dose-response data and fitted BMD models are presented in Supporting
Information Figure S1.
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MOE, tolerable daily intake or TDI, etc.). To this end,
Slob (2017) recently outlined a statistical framework that
can be used to determine meaningful BMRs for toxico-
logical endpoints. The theory predicts a general relation-
ship between the maximum response (i.e., maximum fold
change in response relative to control) and within-group
variation (i.e., variability in response measurements
obtained between animals in a dose-group) for any toxi-
cological endpoint. Demonstrating this relationship using
dose-response data for 27 different endpoints, the work
thus provides a basis for setting BMRs appropriately in
context of each endpoint’s response maximum. Thus, the
theory supports the underlying rationale of the BMR 1-
standard deviation or BMD1SD approach (i.e., where the
control group mean plus one standard deviation is
employed to define the BMR; thus accounting for differ-
ences in the ‘natural variability’ across different end-
points) [Slob, 2017]. However, due to the ubiquitous
errors present in experimental measurements (e.g., due to
limited replications, differences between experimental
animals etc.), instead of using the observed within-group
standard deviation of a specific study as the effect size,
the theory demonstrates that it is better to use the typical
value of the standard deviation. In other words, averaged
across all dose-groups and across a large number of stud-
ies per endpoint. To this end, ongoing efforts are estab-
lishing large datasets that will permit robust estimation of
the within-group variation for selected endpoints (e.g.,
in vivo micronucleus, pigA, and tissue-specific transgenic
rodent assay tests). Since this work has yet to be com-
pleted, in applying the Slob (2017) approach herein, we
are limited to using a rough estimate of the typical
within-group variance based on the few datasets at hand
to define meaningful endpoint-specific BMRs. The values
employed in the below analyses should not yet, therefore,
be regarded as robust endpoint-specific BMR values that
can be used for regulatory purposes, but rather as a pre-
liminary estimate with the purpose of employing a more
reasoned choice for the BMR than just selecting an arbi-
trary value such as 10%.
Applying the aforementioned Slob (2017) approach to
the EMS gpt delta and MutaMouseTM (lacZ) datasets
yielded endpoint-specific BMRs of 45% and 31% for
bone marrow and small intestine, respectively (Fig. 3). In
comparison to the analyses using a BMR of 10% (Fig. 2),
these increases in effect-size (BMR) are seen to improve
the precision in the BMD estimates (i.e. reduce the
BMDU-to-BMDL ratios). This is as expected, since the
increased BMR results in interpolation of the data further
up the dose-response curve; closer to the range of experi-
mental observation where concomitantly, the dose-
response relationship is less uncertain (the reader is
referred to the introduction / Figure 1 for a full visual
explanation of the BMD approach and derivation of the
BMD confidence interval). For small intestine, genotoxic
potency estimates from the two TGR variants span only
0.5 log units (i.e., factor of 3), and show considerable
overlap, suggesting good reproducibility. In contrast, the
bone marrow confidence intervals are now sufficiently
well-resolved to be distinct from one another, indicating a
slightly lower genotoxic potency estimate from the gpt
delta mouse data in comparison with MutaTMMouse.
However, before concluding that these non-overlapping
confidence intervals are indicative of poor TGR variant
Fig. 3. Genotoxic potency of ethyl methanesulphonate (EMS) deter-
mined using the gpt delta mouse (red) and MutaTMMouse (blue) trans-
genic rodent assays: endpoint-specific BMRs. BMD analysis, with
endpoint-specific BMR values, was conducted to compare BMDs deter-
mined across two TGR assay variants. Two-sided 90% confidence inter-
vals of the BMD, based on BMRs indicated beneath each tissue, were
calculated from mutant frequency (MF) dose-response data (i.e., gpt or
lacZ transgene) for bone marrow, small intestine, and liver tissues using
two different BMD models: the exponential (upper interval per pair) or
the Hill (lower interval per pair). Combined analyses were performed,
two datasets at a time by tissue, using TGR as covariate. The underlying
dose-response data and fitted BMD models are presented in Supporting
Information Figure S2.
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reproducibility, it is important to note that the ranges
encompassed by the BMD confidence intervals are only
0.5 log units at most, so, the difference in BMDs is
somewhere between 0 and 0.5 log units (i.e., again, at
most, a factor of 3). BMD model fits to the data are
presented in Supporting Information Figure S2.
ENU: Comparisons of MutaTMMouse (lacZ or cII) and gpt
Delta Mouse Small Intestine Dose-Response Data
Moving to a different compound, ethyl nitrosourea
(ENU), Figure 4 presents a comparison of the potency
estimates derived from matched MutaTMMouse (cII and
lacZ transgenes) and gpt delta mouse datasets. Here,
matching data from two independent studies were further
available for each of the MutaTMMouse assessments.
BMD analyses were carried out by transgene using study
as covariate, with endpoint-specific BMR values esti-
mated from the typical within-group variances across the
available studies for each transgene (i.e., as outlined
above for EMS). When considering the resultant confi-
dence intervals, it is interesting that the two
MutaTMMouse (lacZ) studies show highly similar potency
estimates, whilst the data arising from the two
MutaTMMouse cII studies generated significantly different
(i.e., non-overlapping) confidence intervals. This shows
that even when the same TGR assay variant is employed,
differences in potency estimate can arise, presumably due
to a variety of different experimental factors (e.g., litter,
diets, housing, animal handling, etc.). In this specific
instance, consideration of the data (Supporting Informa-
tion Figure S3) shows that the major difference between
the two cII datasets is related to the control-group values,
with the mean control group (i.e., background) responses
differing by almost an order of magnitude. Interestingly,
above the control, the mean responses for the groups of
experimentally dosed animals are highly similar across
the two studies. This suggests that the control-group in
one of the two studies likely constitutes an outlier attrib-
utable to an unknown experimental factor. With respect
to the design of these studies, both were conducted using
three dose-groups plus control with six animals per dose-
group. The establishment of different potency estimates
as a result of differing control-group values therefore sug-
gests that a more effective study design could have uti-
lized a greater number of dose groups and fewer animals
per group. If this had been the case, the influence of one
outlying group on the calculated BMD confidence interval
may have been reduced [Slob, 2014a; Slob, 2014b].
Regardless, consideration of the BMD confidence inter-
vals also shows that the uncertainty in the genotoxic
potency estimates caused by these different control-group
responses (i.e., lowest BMDL to highest BMDU across
the two studies) is at worst 0.8 log units (factor of 6),
and may in fact be considerably less. Applying the same
logic to the complete set of confidence intervals, includ-
ing those from the gpt delta mouse study, it can be seen
that the genotoxic potency estimates arising from the
three TGR variants could differ by up to 1 order of
magnitude; however, it might also be that they differ by
only 0.3 log units (i.e., a factor of 3: BMDU of gpt
delta mouse to BMDL MutaTMMouse cII study two).
DMN: Comparisons of BigBlueV
R
Mouse (lacI) and
MutaTMMouse (lacZ) Liver Dose-Response Data
The final matched datasets permit comparison of
MutaTMMouse lacZ and BigBlueV
R
mouse lacI DMN
Fig. 4. Genotoxic potency analysis of N-ethyl-N-nitrosourea (ENU)
determined using the MutaTMMouse (cII or lacZ transgenes) or gpt delta
Mouse (gpt transgene) transgenic rodent assays. BMD analysis, with
endpoint-specific BMR values, was conducted to compare BMDs deter-
mined using two TGR assay variants. Two-sided 90% confidence inter-
vals of the BMD, based on BMRs indicated beneath each tissue, were
calculated from mutant frequency (MF) dose-response data (i.e., gpt or
lacZ transgene) for bone marrow, small intestine, and liver tissues using
two different BMD models: the exponential (upper interval per pair) or
the Hill (lower interval per pair). Combined analyses were performed,
two datasets at a time by tissue, using study as covariate. The underlying
dose-response data and fitted BMD models are presented in Supporting
Information Figure S3.
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dose-response data for liver following exposures to
dimethylnitrosamine (DMN) (Fig. 5). Whereas both study
designs were two-dose plus control with four animals per
dose-group the confidence intervals show much greater
BMD estimate precision from the MutaTMMouse data in
comparison to that from BigBlue
VR
. The BMD analysis
(Supporting Information Figure S4) indicates that this is
related to the fact that the within-group variation (var
parameter) in the BigBlue
VR
data was 4-fold greater than
that associated with the MutaTMMouse data. Importantly,
this shows that questions related to the number of animals
required to suitably define a metric such as the BMD are
not easily addressed. The precision of the metric is
heavily influenced by the actual scatter in the experimen-
tal observations (i.e., response measurements) across ani-
mals. Thus, in this particular instance, the utility of the
lacI study to compare the two assays’ potency estimates
is limited. This is reflected in the confidence intervals,
which reveal that, based upon the available data, the dif-
ference between the BMDs could be up to 2 orders of
magnitude. However, due to confidence interval overlap,
it is also possible that the BMDs are in fact highly
similar.
CONCLUSIONS AND RECOMMENDATIONS
Despite considering the entire TRAID database, which
contains over 2000 dose-response datasets, the meta-
analysis only identified 14 suitably-matched datasets that
were thus ideally suited for purposes of comparing BMD-
derived potency estimates. The lack of suitably matched
data inevitably places limitations on what can be con-
cluded with regard to the question of potency estimate
reproducibility across different TGR assay variants. With
this in mind, none of the analyses presented herein across
four commonly used murine TGR variants (i.e.
MutaTMMouse lacZ, MutaTMMouse cII, gpt delta mouse,
and BigBlue
VR
mouse lacI) revealed significantly different
(i.e. non-overlapping) BMD confidence intervals when
assessing matched datasets for the same compound. This
finding was reliant however upon taking into account the
importance of comparing genotoxic potency estimates in
context of dose-response relationship uncertainty. More
specifically, similar to our earlier works [e.g., Bemis
et al. 2016; Wills et al. 2016a,b], we demonstrate that
comparing BMD confidence intervals, as opposed to the
comparison of any single metric (e.g. BMD, BMDL or
BMDU), is essential for robust comparisons of genotoxic
potency estimates.
With these findings in mind, it is useful to note that
our previous work comparing TGR-derived BMDs across
multiple tissues from MutaTMMouse specimens exposed
to the prototypical mutagenic polycyclic aromatic hydro-
carbon benzo[a]pyrene showed significant differences in
genotoxic potency across four out of the five tissues ana-
lyzed (i.e. small intestine, bone marrow, glandular stom-
ach, liver) [Wills et al., 2016b]. Moreover, the BMD
confidence intervals established across these different tis-
sues spanned a dose range of 1.5 orders of magnitude
(i.e., a factor of 30). From a biological perspective, this
seems hardly surprising given the differences in exposure
dosimetry that will be established across tissues by the
complex processes of adsorption, distribution and
compound-specific metabolism. Thus, for generation of
comparable TGR-derived potency estimates, questions
regarding the tissue(s) that should be collected, analyzed,
and subsequently used to derive a PoD, appear to be
equally or potentially more important than questions
related to the choice of TGR assay variant.
With respect to the selection of tissues that can provide
data which are useful for regulatory evaluations of geno-
toxic substances, our results suggests that cryogenic
Fig. 5. Genotoxic potency analysis of dimethylnitrosamine (DMN) deter-
mined using the MutaTMMouse (blue) or BigBlue
VR
Mouse (orange) trans-
genic rodent assays. BMD analysis, with endpoint-specific BMR values,
was conducted to compare BMDs determined using two TGR assay var-
iants. Two-sided 90% confidence intervals of the BMD, based on BMRs
indicated beneath each tissue, were calculated from mutant frequency
(MF) dose-response data (i.e., lacZ or lacI transgene) in liver tissue using
two different BMD models: the exponential (upper interval per pair) or
the Hill (lower interval per pair). Datasets were analyzed individually.
The underlying dose-response data and fitted BMD models are presented
in Supporting Information Figure S4.
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storage of multiple tissues collected at necropsy is a rec-
ommended strategy to avoid the possible necessity of
repeating a costly in vivo study. Regarding tissue choice,
it is suggested that studying multiple tissues, ideally cho-
sen based on known or hypothesized mode of action
(MOA) information, inclusive of any knowledge of simi-
lar compounds’ ADME (adsorption, distribution, metabo-
lism, and excretion) kinetics, provides significantly
greater safeguarding than just studying a single tissue.
For example, despite metabolic competence, liver may
not be ideal due to lower cell proliferation rates and ele-
vated repair that may significantly reduce sensitivity to
mutation [Wills et al., 2016b].
Finally, it is clear that whilst fixed-percentage BMRs
are effective for potency comparisons across covariates,
the use of BMDs for HHRA requires specification of a
meaningful, small BMR size. Consequently, this work
argues that it is essential to tackle the determination of
endpoint-specific effect sizes (i.e. BMRs); especially now
that a statistical framework for understanding the relative
magnitude of effect sizes in dose-response relationships is
becoming established [Slob, 2017]. Use of this approach,
in conjunction with the employment of advanced BMD
methods such as the combined covariate approach, shows
that the BMD method improves the utility of genetic tox-
icity dose-response data by provision of robust, compara-
ble estimates of genotoxic potency.
To summarize, this work offers several conclusions and
recommendations. The first four relate to effective use of
the BMD approach for analysis of genetic toxicity dose-
response data. The last two, which have been identified
as priorities for the Health and Environmental Sciences
Institute Genetic Toxicology Technical Committee
(HESI-GTTC), relate to more specific issues regarding
the reproducibility of potency estimates across TGR assay
variants, and the utility of genetic toxicity PoD estimates
for risk assessment and regulatory decision-making.
1. As noted in the aforementioned earlier works, the
BMD approach provides robust estimates of genotoxic
potency; moreover, the combined covariate approach
can be used to investigate the influence of covariates
such as tissue and assay variant on the derived potency
estimates.
2. International guidelines that harmonize genotoxicity
assay study designs increase the utility of dose-
response data, and thus the use of experimental ani-
mals beyond that of the originating study. This is
achieved through a reduction in the number of influen-
tial covariates, which in turn facilitates subsequent
cross-study comparisons. However, it is suggested that
more routine adoption of study designs employing
fewer animals per dose group, alongside a greater
number of dose-groups, could further improve the
quantitative utility of dose-response data by reducing
the influence of any single outlying group on the calcu-
lated BMD confidence interval.
3. Determining BMDs and associated confidence intervals,
via both the exponential and the Hill model families, is a
recommended best-practice to ensure that the uncertainty
in the estimated BMD is appropriately defined. More-
over, comparisons of potency across covariates should
not be based on one single value such as the BMD,
BMDL or BMDU. Rather, effective comparisons across
covariates, such as assay variant or tissue, requires con-
sideration of BMD confidence intervals.
4. The relative strengths and weaknesses of the BMR%
(i.e., percentage increase above background) and
BMR1SD (i.e., BMR5 control-group mean plus one
control-group standard deviation) approaches can be
reconciled via determination of endpoint-specific
BMR% values. These BMRs should be derived from
the typical endpoint-specific maximum response or the
typical endpoint-specific within-group variation values
i.e., based on a large number of studies for the same
endpoint. Efforts to achieve this for a range of genetic
toxicity endpoints are currently underway.
5. With respect to the reproducibility of genotoxic potency
estimates, we found no evidence that the choice of TGR
assay variant significantly influences compound-specific
BMD determination. Based on these and earlier results,
it might be hypothesized that the choice of tissue for a
given TGR assay variant is equally, or potentially more
important, than the choice of TGR variant itself. Thus,
cryogenic storage of numerous tissues is recommended,
as is genotoxic potency analyses in multiple tissues
selected in consideration of supporting information (e.g.
MOA, ADME kinetics).
6. There is currently no consensus regarding the most prag-
matic methodology to routinely employ in vivo genotox-
icity potency estimates for regulatory decision-making.
Thus, it will be necessary to scrutinize the results of the
current study, as well as our earlier studies and related
studies by other authors, to determine the most appropri-
ate approach. Indeed, some international advisory
groups are currently considering issues regarding the use
of BMD values for regulatory evaluation of genotoxic
test articles such as pharmaceutical impurities and food
contaminants [Benford, 2016; ICH, 2014, 2015].
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